Lyell Immunopharma Inc (NASDAQ: LYEL) kicked off on Friday, down -8.83% from the previous trading day, before settling in for the closing price of $0.59. Over the past 52 weeks, LYEL has traded in a range of $0.48-$3.14.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 332.01% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 48.02%. With a float of $124.87 million, this company’s outstanding shares have now reached $294.88 million.
In an organization with 300 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -16170.49%, operating margin of -591949.18%, and the pretax margin is -562285.25%.
Lyell Immunopharma Inc (LYEL) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Lyell Immunopharma Inc is 57.70%, while institutional ownership is 22.48%. The most recent insider transaction that took place on Mar 21 ’25, was worth 115,220. In this transaction Director of this company bought 200,000 shares at a rate of $0.58, taking the stock ownership to the 200,000 shares. Before that another transaction happened on Mar 14 ’25, when Company’s Director bought 158,000 for $0.60, making the entire transaction worth $94,942. This insider now owns 843,365 shares in total.
Lyell Immunopharma Inc (LYEL) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 48.02% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 21.29% during the next five years compared to -19.90% drop over the previous five years of trading.
Lyell Immunopharma Inc (NASDAQ: LYEL) Trading Performance Indicators
Take a look at Lyell Immunopharma Inc’s (LYEL) current performance indicators. Last quarter, stock had a quick ratio of 7.06. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2663.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.31, a number that is poised to hit -0.18 in the next quarter and is forecasted to reach -0.62 in one year’s time.
Technical Analysis of Lyell Immunopharma Inc (LYEL)
Let’s dig in a bit further. During the last 5-days, its volume was 0.63 million. That was inferior than the volume of 1.04 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 54.38%. Additionally, its Average True Range was 0.07.
During the past 100 days, Lyell Immunopharma Inc’s (LYEL) raw stochastic average was set at 5.91%, which indicates a significant decrease from 25.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 132.24% in the past 14 days, which was higher than the 97.57% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6102, while its 200-day Moving Average is $1.1019. However, in the short run, Lyell Immunopharma Inc’s stock first resistance to watch stands at $0.5953. Second resistance stands at $0.6494. The third major resistance level sits at $0.6788. If the price goes on to break the first support level at $0.5118, it is likely to go to the next support level at $0.4824. The third support level lies at $0.4283 if the price breaches the second support level.
Lyell Immunopharma Inc (NASDAQ: LYEL) Key Stats
The company with the Market Capitalisation of 159.78 million has total of 295,229K Shares Outstanding. Its annual sales at the moment are 60 K in contrast with the sum of -342,990 K annual income. Company’s last quarter sales were recorded 10 K and last quarter income was -191,940 K.
